

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED

普华和顺集团公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

VOLUNTARY ANNOUNCEMENT

(1) EXTENSION OF EXCLUSIVITY PERIOD IN RELATION TO THE ACQUISITION OF CBPO SHARES AND (2) UPDATE OF CONSORTIUM MEMBERS

References are made to the circular of PW Medtech Group Limited (the “**Company**”) dated October 18, 2019 and the announcements of the Company dated September 19, 2019 and January 23, 2020, respectively (the “**Announcements**”) in relation to, among others, the Consortium Agreement and the Acquisition. Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

As disclosed in the Announcements, each party to the Consortium Agreement shall (unless otherwise consented to in writing in advance by the Majority Initial Consortium Members) and shall cause its affiliates to, among other things, work exclusively with the other parties to implement the Acquisition during the Exclusivity Period, which should be up to September 17, 2020.

As additional time is required to implement the Acquisition, the Board announces that after good and valuable consideration, the Company and other Consortium members have entered into an exclusivity extension letter on September 16, 2020 to extend the Exclusivity Period to December 17, 2020.

Concurrently with the entry into the exclusivity extension letter, Mr. Joseph Chow (“**Mr. Chow**”), chairman and chief executive officer of CBPO, executed a deed of adherence to the Consortium Agreement, pursuant to which Mr. Chow joined the Consortium.

Save as disclosed above, all other provisions of the Consortium Agreement are and shall remain in full force and effect.

As the completion of the Acquisition is subject to the satisfaction and/or waiver (where applicable) of the conditions precedent set out in the Consortium Agreement, the Acquisition may or may not materialize. Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
PW Medtech Group Limited
Yue'e Zhang
Chairman & Chief Executive Officer

Beijing, the PRC, September 16, 2020

As at the date of this announcement, the Board comprises one executive Director, namely, Ms. Yue'e Zhang; two non-executive Directors, namely, Mr. Jaing Liwei and Mr. Lin Junshan; and three independent non-executive Directors, namely, Mr. Wang Xiaogang, Mr. Zhang Xingdong and Mr. Chen Geng.